WCLC 2024

WCLC 2024
Call for Abstracts

Abstract Submission is Now Closed

Thank you for your interest. Abstract submissions for WCLC 2024 are now closed. All abstract presenters have now been notified. If you have not received your abstract notification, please check your spam folder. If you have any questions, please contact [email protected].

Abstracts have been released!

Preview 1,800 abstracts being presented at WCLC 2024!

Important dates:

January 31, 2024 
Abstract Submission Opens

July 12, 2024 (23:59 PDT)
Presenting Author Registration Deadline 

April 5, 2024 (23:59 PDT) 
Abstract Submission Deadline

July 23, 2024 (10:00 PDT) 
Abstract Title Release (except LBA)

April 5, 2024 (23:59 PDT) 
Education Awards Application Deadline

July 31, 2024 (23:59 PDT) 
Late-Breaking Abstract Deadline

May 29, 2024 
Notification of Abstract Acceptance (Sent)

August 7, 2024 (23:59 PDT)
Late-Breaking Abstract Notifications

May 29, 2024 
Notification of Education Awards

August 14, 2024 (10:00 PDT)
Full Abstract Release Date
(Except for Embargoed Abstracts)

Abstract Submission Guidelines:

Abstract Submission Guidelines

To foster high-quality oral and written presentations at IASLC conferences, an implementation team will conduct a review of abstract titles and provide suggestions based on the  IASLC Language Guide. We encourage you to review the Guide prior to submitting your abstract, to minimize later suggestions or edits and to help facilitate mutually respectful communication.   

Word Limit: 

500 words (does not include title and authors) 
Abstracts should be organized in different sections based on the selected abstract type. Please refer to the ‘Abstract Type’ section on this page for further information. 

Title Word Limit: 

125 characters total (including spaces) 

Tables: 

No limit; each table counts as 100 words 

Images: 

2 maximum; each image counts as 100 words 

Format(s): 

Upload tables, images and graphs in GIF, JPEG, JPG or PNG format of a minimum of 300 dpi and 100% size. Higher resolution is acceptable and preferred. 

Language: 

English 

Fee: 

No submission fee 

Presenting Author Limit: 

Authors can only be listed as the Presenting Author on two (2) abstracts but can be co-author on any number of abstracts. 

Number of Co-authors: 

No limit of co-authors on any abstract. 

Encore Submission: 
An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract. 

Financial disclosure and affiliation information is required for the presenting author.  For reference, here is a link to the disclosure form. 

Publication:
Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation. 

Education Awards:
These awards are presented to individuals with high scoring abstracts who meet categorical eligibility criteria and who apply. Applications must be completed by the abstract and education award submission deadline April 5, 2024 (23:59 PDT). 

Plagiarism Policy

Definition: 
Plagiarism encompasses all of the following: 

  1. Direct: intentionally submitting another person’s words or ideas verbatim as one’s own; 
  2. Self-plagiarism: submitting work that has been previously published or presented; 
  3. Mosaic plagiarism: stringing together portions of text from other sources; and 
  4. Lack of attribution: failing to appropriately identify and cite sources for language or ideas that are incorporated. 

For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370  

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121267/  

  • Screening: IASLC screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of plagiarized content will be evaluated by IASLC staff and appropriate actions taken. 

  • Penalties for plagiarism may include: Rejection of abstract, and/or author(s) banned from making presentations at IASLC conferences. 
Independence of Educational Activities Policy / Conflict of Interest

Financial disclosure and affiliation information is required for the presenting author.  

For reference, hereis a link to the disclosure form.   


Independence of Educational Activities Policy
 

  • Employees of ACCME defined ineligible companies are prohibited from presenting educational content for Continuing Medical Education. Consequently, employees of ineligible companies are prohibited from giving presentations during accredited CME sessions (e.g., Presidential and plenary symposia, invited educational sessions).  
  • In situations where the presenting author is an employee of an ineligible company, the abstract will automatically be considered for a poster or e-poster.  
  • Presenting authors must be registered for WCLC 2024 independent of an ineligible company, except for employees of ineligible companies, who are allowed to be registered by their employers.  
  • The presenting author must control all content. Ineligible companies may not influence scientific content by requiring the use of company slide decks or other materials. Scientific data generated by industry sponsored research is permissible.  
  • Content of educational activities must be well-balanced, evidence based and unbiased. Generic names should be used to the extent possible.  
  • Ineligible companies/commercial interests may not submit registration materials or fees on behalf of learners, faculty or others attendee types. 
Encore Submissions

An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract. 

Publications

Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference proceedings. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.  


Associated manuscripts for any abstract selected for presentation at WCLC can be submitted to a peer reviewed journal prior to presentation at WCLC but must not be published prior to the presentation at WCLC. Simultaneous publications are encouraged.  

Embargo and Confidentiality

Confidentiality
Upon submission to the WCLC, all abstracts and study data intended for presentation at the Conference are held in confidence. This confidentiality policy applies to previously presented abstracts at WCLC only with regard to new or updated data or information within the study.

Before the abstract information is made public in conjunction with the WCLC Conference, the following parties – the author, co-authors, research sponsor, journalists, and others – are prohibited from:

  • Disclosing the information to the public or sharing it with entities that may make it public, such as news media
  • Using the information for securities trading purposes or providing it to others for such purposes

Confidentiality restrictions are lifted when WCLC publishes the abstracts online in conjunction with the Conference. Once IASLC makes the abstract publicly available, the Confidentiality Policy becomes inactive, allowing authors to openly discuss their study findings. However, formal presentations, including slides, posters, and recordings of the study data, remain exclusive to WCLC.

In cases where an abstract or its data is released in a manner that violates WCLC’s Confidentiality Policy after submission, the abstract may become ineligible for inclusion in the WCLC Conference. Exceptional circumstances may be considered if an official Confidentiality Policy Exception is applicable.

Embargo 
All abstracts accepted for presentation with the exception of abstracts included in the WCLC press program will have their titles released on July 23, 2024 at 10:00 PDT and the full text released on August 14, 2024 at 10:00 PDT.  

Abstracts selected for inclusion in the WCLC press program, including Presidential Sessions abstracts, will be kept under embargo until either the time of the presentation or the beginning of the WCLC press conference in which it is presented, whichever comes first. 

Abstract Submission Tracks:

Risk Factors, Risk Reduction & Tobacco Control

This would include classic epidemiology, family history, gender differences, lung cancer in persons who have never smoked, exposure to radon, tobacco, and asbestos, cessation programs, chemoprevention, and efforts to reduce tobacco production, sales, and distribution. 

Tumor Biology – Preclinical Biology

This would include in vitro basic science studies and cell lines.

Tumor Biology – Translational Biology

This would include patient derived cells, animal models, and drug development studies. 

Screening and Early Detection

This would include low-dose computed tomography (LDCT) and radiology but also ongoing research into other methods and technologies to screen and detect thoracic cancers early. 

Pulmonology and Staging

This would include endoscopic ultrasound (EUS)endobronchial ultrasound (EBUS)navigational bronchoscopy (NB)positron emission tomography (PET)-CT, mediastinoscopy, and staging system analyses. 

Pathology and Biomarkers

This would include anatomic and molecular pathology, tissue and circulating biomarker studies, and clinical trial associated predictive biomarkers.

Early-Stage Non-small Cell Lung Cancer

This would include clinically related studies on localized/early-stage NSCLC, surgery, radiation therapy, neoadjuvant and adjuvant therapies, and immunotherapy and targeted therapies in this setting.

Local-Regional Non-small Cell Lung Cancer

This would include clinically related studies on local-regional/locally advanced NSCLC (Stage III), surgery, radiation therapy, neoadjuvant and adjuvant therapies, immunotherapy and targeted therapies in this setting, and new multi-modality approaches.

Local-Regional Non-small Cell Lung Cancer

This would include clinically related studies on local-regional/locally advanced NSCLC (Stage III), surgery, radiation therapy, neoadjuvant and adjuvant therapies, immunotherapy and targeted therapies in this setting, and new multi-modality approaches.

Metastatic Non-small Cell Lung Cancer – Local Therapies

This would include clinically relevant studies in metastatic/advanced NSCLC related to radiation therapy, surgery, and other ablative techniques.

Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

This would include clinically relevant studies in metastatic/advanced NSCLC related to targeted therapy, including chemotherapy and nonclassical chemotherapy agents (ie ADCs), radiation oncology, new agents, new combinations, and new sequencing of drugs. 

Metastatic Non-small Cell Lung Cancer – Immunotherapy

This would include clinically relevant studies in metastatic/advanced NSCLC related to targeted therapy, including new agents, new combinations including radiation oncology, and new sequencing of drugs. 

Metastatic Non-small Cell Lung Cancer – Targeted Therapy

This would include clinically relevant studies in metastatic/advanced NSCLC related to targeted therapy, including new agents, new combinations including radiation oncology, and new sequencing of drugs. 

Small Cell Lung Cancer and Neuroendocrine Tumors

This would include clinically related studies on small cell lung cancer and neuroendocrine tumors. Strictly translational and basic science studies should go to tumor biology.

Mesothelioma, Thymoma, and Other Thoracic Tumors

This would include clinically related studies on mesothelioma, thymoma, thymic carcinoma, and other thoracic tumors.

Multidisciplinary Care: Nursing, Allied Health and Palliative Care

This would include nursing, allied health, palliative and supportive care, symptom management, decision-making, decision support techniques, ethics, quality of life, integrative care, rehabilitation, physiotherapy, and survivorship care.

Patient Advocacy

This would include patient advocacy, patient survivorship, community outreach, patient-driven research, advocacy and patient foundations and organizations, patient reported outcomes, and lung cancer stigma. 

Global Health, Health Services, and Health Economics

This would include large real-world database studies across tumor types and stages, disparities identification and solutions, studies that examine the cost-effectiveness of therapies, diagnostics, or pathway implementation, programs that help improve the efficiency of health systems or patient management, and registry creation descriptions. 

Abstract Types Accepted:

regular abstract

Definition:  Original scientific research that summarizes work done and major research findings. 

Required sections for abstract submission: 

Clinical Trials in Progress

 (eligible for designation as poster or e-poster only)

Definition:  Ongoing trials that have not reached pre-specified endpoints for analysis.

Required sections:

Optional sections:

Case Series

 (eligible for designation as poster or e-poster only)

Definition:  Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient. Must include a minimum of three (3), but preferably five (5) cases. 

Required sections for abstract submission: 

Late-Breaking Abstract (LBA) Submission

Definition:

  • LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines.
  • LBA designation is not a means for extending the regular abstract deadline. Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.
  • For abstracts that do not meet LBA requirements the authors will be given 48 hours to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.

Submission requirements:
Authors of LBA must submit a place holder abstract through the abstract portal by April 5, 2024 (23:59 PDT).

Required sections for LBA place holder, which must be submitted by the April 5, 2024 deadline:

  • Explanation of why the abstract qualifies as late-breaking
  • Introduction
  • Methods, including applicable endpoints
  • Types of anticipated analysis and data to be reported

LBA Eligibility Review:
The Scientific Program Committee will review LBA placeholder applications after the regular abstract submission deadline April 5, 2024. Authors of approved LBAs will be notified and advised on the processes for submitting final data by July 31, 2024. Authors of abstracts not being granted LBA status will be notified and given 48 hours to submit all available data before the abstract is re-classified as a regular abstract and included in the regular abstract review and scheduling process.

Required sections for final LBA, which must be submitted by July 31, 2024 (23:59 PDT):

  • Introduction
  • Methods, including applicable endpoints
  • Results
  • Conclusion

LBA abstracts not completed by the July 31 deadline will be automatically withdrawn and will not be considered for the meeting. Exceptions may be granted in exceptional circumstances. The Scientific Program Committee will review the final LBA and notify the authors of its disposition by August 7, 2024. Authors must accept/decline the presentation within 48 hours of notification.

Required sections for final LBA, which must be submitted by July 31, 2024: 

Review:  The Scientific Program Committee will review LBA placeholder applications. Authors of approved LBAs will be notified and advised on deadlines and the processes for submitting final data by July 31, 2024. LBA abstracts not completed by this deadline will be automatically withdrawn and will not be considered for the meeting. The Scientific Program Committee will review the final LBA and notify the authors of its disposition by August 8, 2024 

Frequently Asked Questions

Abstract titles will be released July 23, 2024.

The full abstract bodies will be released on August 14, 2024 at 10:00 PDT, except those abstracts included in the WCLC 2024 Press Program.  

 

Abstracts selected for inclusion in the WCLC press program, including Presidential Sessions abstracts, will be kept under embargo until either the time of the presentation or the beginning of the WCLC press conference in which it is presented, whichever comes first.  

An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations during the abstract submission process.

The submission of single case reports is not permitted, however, submission of case series with a minimum of 3 cases but preferably 5, including literature review is accepted. 

July 12, 2024 is the withdrawal deadline for regular abstracts and August 9 for LBA abstracts.
The presenting author registration deadline (except LBA abstracts) is July 12, 2024 (23:59 PDT). Abstract presentations for a presenter (except LBA abstracts) not registered by this date will be withdrawn from the program.

  • LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines. Examples include randomized phase II and/or III trials, and large single arm phase II trials in rare subtypes of thoracic malignancies. LBA’s in other disciplines that change clinical practice within the year will also be considered.
  • LBA designation is not a means for extending the regular abstract deadline. Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.
  • For abstracts that do not meet LBA requirements the authors will be given 48 hours to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.

Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract. However, Industry/pharmaceutical/commercial authors are prohibited from presenting Presidential, Oral, and Mini Oral presentations. Industry/pharmaceutical/commercial authors are permitted to present poster or e-poster presentations. 

Associated manuscripts for any abstract selected for presentation at WCLC can be submitted to a peer reviewed journal prior to presentation at WCLC but must not be published prior to the presentation at WCLC. Simultaneous publications are encouraged. 

All Regular Abstracts, Clinical Trials in Progress Abstracts, and Case Series abstracts must be fully completed by the April 5, 2024 deadline.

Any Regular Abstracts and Case Series that are incomplete after the April 5, 2024 deadline will be automatically withdrawn and will not be considered for the meeting. Clinical Trials in Progress abstracts may be submitted and completed by the April 5, 2024 deadline without Results and Conclusions as those sections are optional for CTPS submissions.

To submit a late breaking abstract, you must submit a placeholder abstract including all components of the abstract except for the Results and Conclusions by the April 5, 2024 deadline.

Authors can only be listed as the Presenting Author on two (2) abstracts but can be co-author on any number of abstracts. 

The authors of the abstract, however, IASLC reserves the right to sell and retain any revenue/income from selling the abstracts, presentation materials or recordings of the presentations. Please refer to the detailed terms and conditions that authors have to agree to during the abstract submission.

Copyright is with the authors, however, IASLC reserves the right to publish and sell copies/recordings of the presentation materials.

The clinical trials must be registered in clinicaltrials.gov or an applicable one from their country/regulatory body.

No. You need to attend WCLC 2024 in person to present your abstract.

The video platform will be available for 3 months after WCLC.

contact Us

For inquiries, please contact  wclc2024[email protected]

If your inquiry is regarding a particular draft or submission,
please include the abstract ID in your email.
 

Scroll to Top